Navigation Links
BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments
Date:3/27/2008

Oncolix, Inc. Selects CryoStor(TM) for Cryopreservation of Cell-Based

Melanoma Therapy

BOTHELL, Wash., March 27 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today provided updated information on the adoption of its products in the cellular therapy and cord blood banking market segments.

BioLife announced that Oncolix, Inc., a biopharmaceutical company based in Greenville, South Carolina, is developing a potential lifesaving treatment for stage IV melanoma and has adopted CryoStor for the cryopreservation of the Company's proprietary dendritic cell-based cancer therapy. Michael Redman, President and CEO of Oncolix, commented on the selection of CryoStor for the company's novel treatment for stage IV melanoma by stating, "We evaluated other commercial cryopreservation media as well as an in-house formulation and found that CryoStor clearly offered post-preservation improvement in cellular yield and function without the use of human serum. Our 25-patient phase II clinical trial will commence within a few weeks so we're quite pleased that this variable in our development process has been locked down."

BioLife Chairman and CEO Mike Rice also commented on the use of CryoStor for the cryopreservation of umbilical cord blood: "The worldwide cord blood banking market is experiencing significant growth. We are currently supporting evaluations of CryoStor at several of the largest cord blood banks in the US, Europe, and Asia, and are optimistic that the results of these evaluations will mimic earlier published data about the advantages CryoStor and could lead to further product adoption in this key market."

Rice then remarked on the growing adoption of BioLife products in two strategic market segments: "We're happy to report that we have gained numerous new customers in the cellular therapy market as a result of repeatedly demonstrated improvements in yield, quality, and costs related to biopreservation of biologic source material and manufactured cell therapy products. Over one hundred cell therapy companies have evaluated or adopted HypoThermosol(R) and/or CryoStor for use in the production of novel cellular therapy products targeting a multitude of diseases and disorders such as cancer, heart failure, vision loss, neurologic disorders, and many others. Our products also extend the shelf life and transport time of both very precious blood and tissue based source material as well as for final cell-based clinical products. Several customers have commented that use of our products is critical to enabling eventual commercialization of their cell-based therapies."

About Oncolix

Oncolix is a drug development company focused on treatments for cancer. The company is currently evaluating Melaxin(R), a cellular therapy, for the treatment of metastatic melanoma in a Phase IIa clinical trial. In addition, the Company has a prolactin receptor antagonist (Prolanta(R)) for the treatment of breast cancer, which is expected to be evaluated in a Phase I trial in early 2009.

About BioLife Solutions

BioLife Solutions develops and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of preservation media products are marketed to academic research institutions, clinical care provider organizations, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides research and clinical organizations significant improvement in post-preservation cell and tissue and viability and function. For more information please visit http://www.biolifesolutions.com.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Media Relations: Investor Relations:

Len Hall Dan Matsui

Allen & Caron Inc. Allen & Caron Inc.

(949) 474-4300 (949) 474-4300

len@allencaron.com d.matsui@allencaron.com


'/>"/>
SOURCE BioLife Solutions Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ken Sperling to Lead CIGNA HealthCare Retiree Solutions Unit
2. Frances Decker Named Mid-Atlantic Region Sales Executive for AllOne Health Management Solutions
3. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
4. SXC Health Solutions to present at the 2007 UBS Global Life Sciences Conference
5. The Village Company Unveils Natural Bath and Body Solutions for Everyday Ailments
6. RESolutions Rapid Enrollment Solutions, LLC Mobilizes Team of Regional Recruitment Specialists(TM)
7. MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions
8. Ingenious Med Forms Multiple Billing Company Partnerships to Market Inpatient Practice Management Solutions
9. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
10. SYMX Builds on Top of New Microsoft Technologies to Offer Hospitals Real-Time Business and Patient Safety Solutions Using RFID Data
11. InfoLogix Signs Largest International Deal to Date with Healthcare Solutions Agreement in United Arab Emirates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... 2017 , ... The International Essential Tremor Foundation (IETF) will host a free ... The seminar will take place on Saturday, Aug. 26 at the Embassy Suites by ... run from 9 a.m. to 12 p.m., with check-in beginning at 8 a.m. The ...
(Date:7/24/2017)... ... July 24, 2017 , ... A CDC study shows that, although people are taking more steps ... to 29), had at least one case of sunburn within the past year. It’s common ... to ignore the issue. However, only recently have people become conscientious of the risks that ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... management solution focused on delivering end-to-end sleep health care at scale, indicates ... literature shows that adherence rates for positive airway pressure (PAP) therapy, the most ...
(Date:7/24/2017)... PA (PRWEB) , ... July 24, 2017 , ... Summer ... rain storms wreak havoc across communities and often result in massive tree damage requiring ... actions homeowners can take now including tree trimming, tree cabling and hazardous tree removal. ...
(Date:7/24/2017)... , ... July 24, 2017 , ... “The Perfect Gift”: a customizable and interactive Bible ... Tosha Huckett is a born-again Christian. She has always accepted Christ as her ... Lord. She was in the Spirit when she wrote this book to her children, ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)...  Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe ... from painful intercourse and other painful pelvic pain conditions such as pelvic ... ... ... Florida -based start-up company, VuVatech LLC, fills a void in the ...
(Date:7/10/2017)... 10, 2017 The Institute for In Vitro ... the recipient of a VITROCELL® inhalation exposure system thanks ... Consortium. The device, which is designed to replace animals ... lung cells to airborne test materials in an environment ... VITROCELL® system for testing combustible tobacco products, as well ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences Inc. ... to support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing ... a leading Chinese Internet services provider, and joined by ... multiple infectious disease product programs targeting antibiotic resistant infections ... Founded by Dr. Rodolphe Barrangou and ...
Breaking Medicine Technology: